 The primary objective of this study was to assess the effect of cytochrome P450 3A4 enzyme CYP3A4 induction by rifampicin on the pharmacokinetics PK of eribulin mesylate following intravenous IV administration in participants with advanced solid tumors. The secondary objectives of this study were to assess the safety of eribulin mesylate when co-administered with rifampicin and assess the safety and activity of eribulin mesylate as a single agent. 